Buy Cipla 600 Call, Cadila Healthcare 300 Call: VK Sharma

VK Sharma, Head Private Broking & Wealth Management at HDFC Securities told CNBC-TV18, "Couple of pharmaceutical names that are spoken about are Cadila Healthcare and Cipla. Cipla has continued to move up and define the general trend in the F&O pharmaceutical segment and my sense is it could still do further. So, I suggesting in Cipla to buy the 600 Call at Rs 11.80 with stop loss at Rs 8 and target of around Rs 20." "The other stock that I have is Cadila Healthcare. Just in order to ensure that there is some room for investors to buy, should the stock fall slightly, so I am suggesting to buy the 300 Call at around Rs 10; although it had closed yesterday at Rs 11.25, I am suggesting that it can be bought at Rs 10 with stop loss of Rs 7 and target of around Rs 15," he said.